← Back to Search
Biofunctionalized Targeted Nanoparticles For Therapeutic Applications
A. Wang, F. Gu, L. Zhang, Juliana M. Chan, A. Radovic-Moreno, Mariam R Shaikh, O. Farokhzad
Published 2008 · Chemistry
Download PDFAnalyze on Scholarcy
Background: The development of nanoparticles for the delivery of therapeutic agents has introduced new opportunities for the improvement of medical treatment. Recent efforts have focused on developing targeted nanoparticles, which are formulated by (for therapeutic delivery) functionalizing nanoparticle surfaces with targeting molecules, such as antibodies, peptides, small molecules and oligonucleotides. Objectives: To review the state of targeted nanoparticles development. Methods: The authors discuss the nanoparticle platforms for therapeutic delivery, targeting molecules and the biofunctionalized targeted nanoparticles currently in development. Results/conclusions: Biofunctionalized targeted nanoparticles have demonstrated exciting results in preclinical studies. With continued improvements, they may fulfill their potential as therapeutics carriers that can deliver the maximum dose to diseased tissue while minimizing effects on normal cells.
This paper references
Inflammation in Atherosclerosis: Visualizing Matrix Metalloproteinase Action in Macrophages In Vivo
J. Deguchi (2006)
Polymers for the sustained release of proteins and other macromolecules
R. Langer (1976)
The origin of pegnology.
F. F. Davis (2002)
Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance
L. R. Hirsch (2003)
Designer genes: recombinant antibody fragments for biological imaging.
A. Wu (2000)
Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma
L. Harris (2002)
Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME).
T. Tanaka (2004)
Development and regulation of monoclonal antibody products: Challenges and opportunities
W. Weinberg (2005)
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.
J. Yang (2003)
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
J. Park (2002)
Polymer conjugates as anticancer nanomedicines
R. Duncan (2006)
Biopharmaceutical drug discovery using novel protein scaffolds.
Davinder S Gill (2006)
Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts.
S. Hu (1996)
The emerging nanomedicine landscape
Volker Wagner (2006)
SELEXION. Systematic evolution of ligands by exponential enrichment with integrated optimization by non-linear analysis.
D. Irvine (1991)
Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.
D. Kirpotin (2006)
Drug delivery and targeting.
R. Langer (1998)
Targeted nanoparticle-based drug delivery and diagnosis
D. Emerich (2007)
Controlled and modulated release of basic fibroblast growth factor.
E. Edelman (1991)
Target-specific cellular uptake of PLGA nanoparticles coated with poly(L-lysine)-poly(ethylene glycol)-folate conjugate.
S. H. Kim (2005)
Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer.
J. Kukowska-Latallo (2005)
Recent advances with liposomes as pharmaceutical carriers
V. Torchilin (2005)
In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics.
Ann-Charlott Steffen (2005)
Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.
H. Hurwitz (2005)
Poly(lactic acid)-poly(ethylene glycol) nanoparticles as new carriers for the delivery of plasmid DNA.
C. Pérez (2001)
In vitro genetic analysis of the Tetrahymena self-splicing intron
R. Green (1990)
An in vitro selected binding protein (affibody) shows conformation-dependent recognition of the respiratory syncytial virus (RSV) G protein.
M. Hansson (1999)
Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor.
L. Green (1995)
Biodegradable long-circulating polymeric nanospheres.
R. Gref (1994)
Stealth PLA-PEG Nanoparticles as Protein Carriers for Nasal Administration
M. Tobío (2004)
Long-circulating and target-specific nanoparticles: theory to practice.
S. Moghimi (2001)
Preparation and characterization of carbonyl iron/poly(butylcyanoacrylate) core/shell nanoparticles.
J. L. Arias (2006)
Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery.
A. Kabanov (2002)
Nanotechnology based drug delivery system(s) for the management of tuberculosis.
R. Pandey (2006)
New methods of drug delivery.
R. Langer (1990)
Designing materials for biology and medicine
R. Langer (2004)
Selection in vitro of single-stranded DNA molecules that fold into specific ligand-binding structures
A. Ellington (1992)
Nanoparticle-based diagnosis and therapy.
D. Groneberg (2006)
Controlled assembly of dendrimer-like DNA
Y. Li (2004)
Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology.
A. Khaled (2005)
Efficient cancer therapy with a nanobody-based conjugate.
Virna Cortez-retamozo (2004)
Small antibody mimetics comprising two complementarity-determining regions and a framework region for tumor targeting
Xiaoqing Qiu (2007)
2′-Fluoropyrimidine RNA-based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF165)
J. Ruckman (1998)
Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design.
K. Beekman (2006)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
E. H. Romond (2005)
About Dendrimers: Structure, Physical Properties, and Applications.
A. W. Bosman (1999)
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
B. E. C. Oiffier (2002)
Selection of high affinity RNA ligands to the bacteriophage R17 coat protein.
D. Schneider (1992)
Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase.
C. Tuerk (1990)
Development of ligand-targeted liposomes for cancer therapy
C. Noble (2004)
Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers
F. Gu (2008)
Folate-mediated delivery of macromolecular anticancer therapeutic agents.
Y. Lu (2002)
Dendrimers in biomedical applications--reflections on the field.
Sönke Svenson (2005)
In vitro selection of functional nucleic acids.
D. Wilson (1999)
Preclinical safety testing of biotechnology-derived pharmaceuticals
F. R. Brennan (2004)
Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.
B. Uziely (1995)
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.
O. Farokhzad (2006)
Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumor-bearing mice.
M. Oyewumi (2004)
Antigenic crossreactivity of the alpha subunit of complement component C8 with the cysteine-rich domain shared by complement component C9 and low density lipoprotein receptor.
J. Tschopp (1986)
O. Farokhzad (2004)
Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer.
Y. Matsumura (2004)
Micellar Nanocarriers: Pharmaceutical Perspectives
V. Torchilin (2006)
Aptamer therapeutics advance.
J. F. Lee (2006)
How to stabilize phospholipid liposomes (using nanoparticles).
L. Zhang (2006)
Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging
D. Bartlett (2007)
This paper is referenced by
TARGETED THERAPY FOR LIVER FIBROSIS AND CANCER
Y. Zhang (2014)
Biodegradable nanoparticles meet the bronchial airway barrier: how surface properties affect their interaction with mucus and epithelial cells.
S. Mura (2011)
Radioisotopes and Nanomedicine
N. Sheets (2011)
LIPID–POLYMER HYBRID NANOPARTICLES: SYNTHESIS, CHARACTERIZATION AND APPLICATIONS
Li I. Zhang (2010)
Nanophysics and Antiviral Therapy
V. Lysenko (2013)
Enhanced Vascular Permeability in Solid Tumors: A Promise for Anticancer Nanomedicine
Sebastien Taurin (2013)
Recent advancements in nanotechnological strategies in selection, design and delivery of biomolecules for skin regeneration.
Purna Sai Korrapati (2016)
Translational Peptide-associated Nanosystems: Promising Role as Cancer Vaccines.
E. Zupančič (2016)
Tumour-specific uptake of anti-cancer drugs: the future is here.
M. Caraglia (2012)
On the cellular processing of non-viral nanomedicines for nucleic acid delivery: mechanisms and methods.
D. Vercauteren (2012)
Anticancer Agents: Polysaccharide-Based Nanocarriers for Drug Delivery
Raje Chouhan (2015)
Delivery of Cancer Nanotherapeutics
Bomy Lee Chung (2019)
Enzyme delivery using protein-stabilizing and cell-penetrating 30Kc19α protein nanoparticles
Hee Ho Park (2017)
Targeting nanoparticles to cancer.
M. Wang (2010)
Engineered nanoparticles as a precise delivery system in cancer therapeutics
R. Sharma (2016)
Targeted gold nanoshells
Burapol Singhana (2015)
Nanotechnology as Emerging Tool for Enhancing Solubility of Poorly Water-Soluble Drugs
S. Kumar (2012)
Studies on the effect of AgNP binding on α-amylase structure of porcine pancreas and Bacillus subtilis by multi-spectroscopic methods
Vinita Ernest (2014)
Aptamer–Liposome Conjugates: Current Art and Future Prospects
O. Ries (2016)
CANCER DIAGNOSTICS, IMAGING AND TREATMENT BY NANOSCALE STRUCTURES TARGETING
Özcan Öznur Özge (2019)
Nanoparticulate Systems for Growth Factor Delivery
S. Zhang (2009)
PEG2000-DPSE-coated quercetin nanoparticles remarkably enhanced anticancer effects through induced programed cell death on C6 glioma cells.
G. Wang (2013)
pH-Responsive Theranostic Polymer-Caged Nanobins (PCNs): Enhanced Cytotoxicity and T1 MRI Contrast by Her2-Targeting.
B. Hong (2013)
Non-invasive and quantitative in vivo monitoring of gold nanoparticle concentration and tissue hemodynamics by hybrid optical spectroscopies.
M. Mireles (2019)
Nanoparticles in bioimaging
J. L. P. Ucha (2013)
Metallic Nanoparticles: Potential Antimicrobial and Therapeutic Agents
Pragati Jamdagni (2018)
Targeted Delivery of Nanomedicines
V. Khanna (2012)
Nanotechnology: A novel approach towards cancer treatment
Rahul Goyal (2014)
Atomic Force Microscopy as a Tool to Assess the Specificity of Targeted Nanoparticles in Biological Models of High Complexity
C. P. Gomes (2017)
Nanomanufacturing: A Perspective.
J. Liddle (2016)
Decreased reticuloendothelial system clearance and increased blood half-life and immune cell labeling for nano- and micron-sized superparamagnetic iron-oxide particles upon pre-treatment with Intralipid.
L. Liu (2013)
Advanced optical imaging reveals the dependence of particle geometry on interactions between CdSe quantum dots and immune cells.
J. Aaron (2011)See more